8-K/AOther Events

ABBOTT LABORATORIES 8-K/A Report (May 14, 2001)

Filed May 14, 2001For Securities:ABT

Summary

This 8-K/A filing by Abbott Laboratories on May 13, 2001, serves as an amendment to a previous report filed on March 2, 2001. The primary purpose of this amendment is to formally file crucial financial exhibits related to Abbott's acquisition of BASF's pharmaceutical business. Investors should note that the filing includes consolidated financial statements for the acquired BASF pharmaceutical business for the years 2000 and 1999, as well as pro forma financial information that combines the results of both Abbott and the acquired BASF assets. This amended filing is significant as it provides key financial details necessary for investors to evaluate the financial impact and potential accretion of the BASF pharmaceutical business acquisition on Abbott Laboratories. The inclusion of these financial statements and pro forma data allows for a more comprehensive understanding of the transaction's scale and its expected contribution to Abbott's overall financial performance.

Key Highlights

  • 1Abbott Laboratories filed an amendment (8-K/A) to its March 2, 2001, Current Report.
  • 2The amendment's purpose is to include Exhibits 99.1 and 99.2.
  • 3Exhibit 99.1 contains consolidated financial statements for BASF's pharmaceutical business for the years ended December 31, 2000, and 1999.
  • 4Exhibit 99.2 presents pro forma financial information combining Abbott Laboratories and the acquired BASF Pharmaceutical Business.
  • 5These exhibits are essential for understanding the financial implications of Abbott's acquisition of BASF's pharmaceutical business.
  • 6The filing incorporates by reference previously filed purchase agreements and a press release related to the transaction.

Frequently Asked Questions

This filing is an amendment to a previous 8-K report, primarily to formally include important financial exhibits (Exhibits 99.1 and 99.2) related to Abbott Laboratories' acquisition of BASF's pharmaceutical business. These exhibits provide financial statements of the acquired business and pro forma financial information.

The filing includes consolidated financial statements for BASF's pharmaceutical business for the years 2000 and 1999 (Exhibit 99.1) and pro forma financial information that presents the combined financial picture of Abbott Laboratories and the acquired BASF pharmaceutical business (Exhibit 99.2).

The acquisition is significant as it represents a material expansion for Abbott's pharmaceutical segment. The financial statements and pro forma information provided in this filing allow investors to assess the size, financial health, and potential future contributions of the acquired business to Abbott's overall revenue and profitability.

Yes, the filing incorporates by reference several other documents, including the Amendment to Purchase Agreement, the original Purchase Agreement, and a press release dated March 2, 2001, all related to the BASF acquisition. It also lists consents from various accounting firms.